Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 10/20 | 0.44 |
| ▸ | HTR1B | P28222 | 9/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR1F | P30939 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24461315 | 0.88 | KDM4E (0.39) | KDM4EATMSMARCA2SMARCA4PBRM1 | |
| SCHEMBL25467865 | 0.88 | PBRM1 (0.40) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL24461134 | 0.87 | BRD4 (0.56) | HTR1DHTR1BHTR1AHTR1FKDM4E | |
| SCHEMBL29619417 | 0.86 | IKBKB (0.48) | APPSMARCA2SMARCA4PBRM1 | |
| SCHEMBL22777062 | 0.86 | IKBKB (0.48) | APPSMARCA2SMARCA4PBRM1 | |
| SCHEMBL24461290 | 0.83 | PBRM1 (0.40) | SMARCA2SMARCA4PBRM1 | |
| SCHEMBL30552534 | 0.83 | PBRM1 (0.40) | SMARCA2SMARCA4PBRM1 | |
| SCHEMBL24461244 | 0.83 | BRD4 (0.48) | KDM4ESMARCA2SMARCA4PBRM1 | |
| SCHEMBL22777626 | 0.82 | SMARCA2 (0.54) | MAPTKDM4ESMARCA2SMARCA4PBRM1 | |
| SCHEMBL24461294 | 0.82 | IKBKB (0.44) | SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2020251972-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | CYP1A2 4083/4885CYP3A4 4079/4885CYP2D6 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.